Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.
In elderly patients with acute myeloid leukemia (AML) treated intensively, no best postremission strategy has emerged yet. This clinical trial enrolled 416 patients with AML aged 65 years or older who were considered eligible for standard intensive chemotherapy, with a first randomization comparing idarubicin with daunorubicin for all treatment sequences. After induction, an ambulatory postremission strategy based on 6 consolidation cycles administered monthly in outpatients was randomly compared with an intensive strategy with a single intensive consolidation course similar to induction. Complete remission (CR) rate was 57% with 10% induction deaths, and estimated overall survival was 27% at 2 years and 12% at 4 years, without notable differences between anthracycline arms. Among the 236 patients who reached CR, 164 (69%) were randomized for the postremission comparison. In these patients, the multivariate odds ratio in favor of the ambulatory arm was 1.51 for disease-free survival (P.05) and 1.59 for overall survival from CR (P.04). Despite repeated courses of chemotherapy associated with a longer time under treatment, the ambulatory arm was associated with significantly shorter rehospitalization duration and lower red blood cell unit and platelet transfusion requirements than observed in the intensive arm. In conclusion, more prolonged ambulatory treatment should be preferred to intensive chemotherapy as postremission therapy in elderly patients with AML reaching CR after standard intensive remission induction.
Gardin
Claude
C
Department of Hematology, Hôpital Avicenne, University Paris 13, Bobigny, France.
Turlure
Pascal
P
Fagot
Thierry
T
Thomas
Xavier
X
Terre
Christine
C
Contentin
Nathalie
N
Raffoux
Emmanuel
E
de Botton
Stephane
S
Pautas
Cecile
C
Reman
Oumedaly
O
Bourhis
Jean-Henri
JH
Fenaux
Pierre
P
Castaigne
Sylvie
S
Michallet
Mauricette
M
Preudhomme
Claude
C
de Revel
Thierry
T
Bordessoule
Dominique
D
Dombret
Herve
H
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D001803:Blood Transfusion; D003630:Daunorubicin / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D006760:Hospitalization; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage*; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D012074:Remission Induction; D015996:Survival Rate
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D015255:Idarubicin; D003630:Daunorubicin